Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer

Inclusion Criteria: * Histologically or cytologically verified colorectal adenocarcinoma. * Patients to receive first line treatment of metastatic disease, including potentially resectable or non-resectable disease * \> 6 months without recurrence after end of adjuvant chemotherapy for radically treated stage II or III colorectal cancer * Disease evaluable according to RECIST 1.1, but not necessarily measurable disease. * Age 18-75 years * Performance status (PS) 0-1. If age 71-75, then PS 0 * Life expectancy \> 3 months * Organ and bone marrow function as follows: * Neutrophil count ≥ 1.5 x 10\^9/L * Thrombocytes ≥ 100 x 10\^9/L * Total bilirubin ≤ 1.5 x upper level of normal (ULN) * Alanine transaminase (ALAT) ≤ 2.5 x ULN (or≤ 5 x ULN in case of liver metastases) * Fertile women must present negative pregnancy test. Male (with a female fertile partner) as well as female patients must use secure contraceptives during and 6 months after end of treatment. * Orally and written informed consent to treatment and biobank Exclusion Criteria: * Primarily resectable metastases * Chemotherapy, radiotherapy or immunotherapy within 4 weeks * Known neuropathy ≥ grade 2 * Serious competitive medical condition * Other concurrent malignant disease other than non-melanoma skin cancer * Previous serious and unexpected reactions to 5-fluorouracil, calcium folinate, oxaliplatin, irinotecan or capecitabine. * Hypersensitivity to one or more of the active substances or auxilliary agents